TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11447952

Group type: EXPERIMENTAL
Intervention: 8 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 25
Study: 9727815

Group type: EXPERIMENTAL
Intervention: Thrice weekly buprenorphine maintenance in primary care clinic
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional drug treatment program
Number of subjects: 46
Study: 7498559

Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine (CSA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No CSA
Number of subjects: 43
Study: 2683836

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 4 puffs of 50 micrograms b.i.d.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1114148

Group type: EXPERIMENTAL
Intervention: Salbutamol (predominantly β‐2 stimulant)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Practolol (predominantly β‐1 blocking agent) with Salbutamol
Number of subjects: 9
Study: 31630236

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS) patients
Number of subjects: 3763

Group type: COMPARATOR
Intervention: Control group (non-AS subjects)
Number of subjects: 3763
Study: 31715435

Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 14671

Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 14671
Study: 28629468

Group type: EXPERIMENTAL
Intervention: Capillary glucose testing during antenatal care, followed by nutritional counselling and follow-up.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard practice for screening and initial management of GDM.
Number of subjects: 20
Study: 26138425

Group type: EXPERIMENTAL
Intervention: Sustained inflation with 30 cmH2O
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sustained inflation with 35 cmH2O
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sustained inflation with varying pressures (P1, P2, P3, P4)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (P0)
Number of subjects: 150
Study: 24080100

Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling and root planing for a minimum of two 90-minute sessions, plus antibacterial mouth rinse for at least 32 days)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (received periodontal treatment after 6 months)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 600
Study: 20847112

Group type: EXPERIMENTAL
Intervention: Laser scanning confocal microscopy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tea tree oil treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (8 age- and sex-matched control subjects)
Number of subjects: 15
Study: 18374327

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (age and gender-matched blood donors)
Number of subjects: 102
Study: 16595275

Group type: EXPERIMENTAL
Intervention: Implementation intention instructions
Number of subjects: 535

Group type: COMPARATOR
Intervention: No implementation intention instructions (Control)
Number of subjects: 535
Study: 12559540

Group type: EXPERIMENTAL
Intervention: Coronary spastic angina (CSA)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Stable effort angina (SEA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Stable effort angina (SEA) with small, dense LDL
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Coronary spastic angina (CSA) with small, dense LDL
Number of subjects: 145
Study: 10698242

Group type: EXPERIMENTAL
Intervention: Intervention group received educational brochures, telephone calls from senior volunteers, and computerized immunization tracking.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group, details not specified.
Number of subjects: 0
Study: 9070556

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 7828454

Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone (0.3 mg/kg/week) administered daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methionyl growth hormone (0.3 mg/kg/week) administered 3 times per week (TIW)
Number of subjects: 20
Study: 3513581

Group type: EXPERIMENTAL
Intervention: Oral progesterone (4 capsules of 100 mg each)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (4 capsules)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oral progesterone
Number of subjects: 57
Study: 29894513

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (High-AEX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (Mod-AEX)
Number of subjects: 22
Study: 27254811

Group type: EXPERIMENTAL
Intervention: LoTor group (spherical orthokeratology lenses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HiTor group I (spherical orthokeratology lenses with conventional fitting)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HiTor group II (spherical orthokeratology lenses with deeper sagittal height)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison between LoTor group and HiTor group I
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison between HiTor group I and II
Number of subjects: 33

Group type: COMPARATOR
Intervention: LoTor and HiTor group I combined
Number of subjects: 33
Study: 25109375

Group type: EXPERIMENTAL
Intervention: Internet-based telemonitoring (AllergyMonitor™)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 63
Study: 22954616

Group type: EXPERIMENTAL
Intervention: Org 26576 (450 mg BID)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Org 26576 (400 mg BID)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Org 26576
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20195651

Group type: EXPERIMENTAL
Intervention: Bracing treatment for idiopathic scoliosis
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control arm (existing treatment)
Number of subjects: 4
Study: 17934033

Group type: EXPERIMENTAL
Intervention: Canadian Quality Circle (CQC) educational intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 15625582

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inspiratory pressure support
Number of subjects: 16
Study: 11908492

Group type: EXPERIMENTAL
Intervention: E‐100 (estradiol, 100 microg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: E‐50 (estradiol, 50 microg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (P‐100, placebo to E‐100)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (P‐50, placebo to E‐50)
Number of subjects: 160
Study: 10461109

Group type: COMPARATOR
Intervention: Tamm‐Horsfall protein excretion in pure uric acid stone formers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uric acid excretion in pure uric acid stone formers (group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uric acid excretion in mixed stone formers (group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium excretion in mixed stone formers (group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Citrate excretion in both groups (I and II)
Number of subjects: 20
Study: 8903836

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 3 IU m‐2 daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 6 IU m‐2 daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2784831

Group type: EXPERIMENTAL
Intervention: Structured teaching with a written guide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unstructured method of education
Number of subjects: 60
Study: 29732483

Group type: EXPERIMENTAL
Intervention: PRO-SMART application
Number of subjects: 101
Study: 28800725

Group type: EXPERIMENTAL
Intervention: Investigational prototype thermal compression device (full device group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intraoperative forced air warming (FAW)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Investigational prototype thermal compression device (single heating area)
Number of subjects: 36
Study: 26151676

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg plus prednisone/prednisolone 5 mg twice daily
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo plus prednisone/prednisolone 5 mg twice daily
Number of subjects: 350
Study: 24477726

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IAI
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fluoroscopy-guided IAI
Number of subjects: 71
Study: 21948888

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19917838

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Induction chemotherapy with cisplatin and fluorouracil (PF)
Number of subjects: 265
Study: 16825692

Group type: EXPERIMENTAL
Intervention: Egg yolk folate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Spinach folate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Yeast folate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12752352

Group type: EXPERIMENTAL
Intervention: 1.5 g sachet (micropellets) mesalazine formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Three enteric‐coated tablets (500 mg each, Claversal)
Number of subjects: 24
Study: 10772034

Group type: EXPERIMENTAL
Intervention: Pulmonary autograft (group A, n = 97)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Aortic homograft (group H, n = 85)
Number of subjects: 182
Study: 9311056

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (2 x 1,000 micrograms/day)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 8370292

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (postoperative cardiac surgery patients)
Number of subjects: 10
Study: 3487259

Group type: EXPERIMENTAL
Intervention: 30 mg/kg bw methylprednisolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg/kg bw dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg/kg hydrocortisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% NaCl as placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 60
Study: 28956658

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet plus 7 grams of psyllium powder (MoCyllium group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lower carbohydrate diet plus placebo powder (LoCarb group)
Number of subjects: 37
Study: 27171828

Group type: EXPERIMENTAL
Intervention: Nociception Level (NoL) index
Number of subjects: 58

Group type: COMPARATOR
Intervention: Other measures of nociception (heart rate, pulse plethysmograph amplitude, noninvasive blood pressure, surgical pleth index)
Number of subjects: 58
Study: 24988874

Group type: EXPERIMENTAL
Intervention: CKDu patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-CKDu subjects
Number of subjects: 0
Study: 22668622

Group type: EXPERIMENTAL
Intervention: Amlexanox paste (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dexamethasone paste (n = 18)
Number of subjects: 38
Study: 20862938

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rehabilitation (group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Rehabilitation training (group B)
Number of subjects: 53
Study: 17973165

Group type: EXPERIMENTAL
Intervention: KR (Knowledge of Results)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: KR + instruction
Number of subjects: 9

Group type: COMPARATOR
Intervention: No KR
Number of subjects: 9
Study: 16570889

Group type: EXPERIMENTAL
Intervention: Auto-transfusion system with re-infusion of drained blood
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Methylprednisolone administration before blood re-perfusion
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard vacuum drains
Number of subjects: 155
Study: 12618164

Group type: EXPERIMENTAL
Intervention: Physiotherapist-delivered urinary continence promotion programme (training in pelvic floor exercises and adherence-enhancing strategies)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Physiotherapist-delivered urinary continence promotion programme
Number of subjects: 348

Group type: COMPARATOR
Intervention: Usual postpartum care
Number of subjects: 348
Study: 10930149

Group type: COMPARATOR
Intervention: AZT 100 mg three times daily plus ddC 0.375 mg three times daily (half dose)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AZT 200 mg three times daily plus ddC 0.75 mg three times daily (standard dose)
Number of subjects: 111
Study: 9513028

Group type: EXPERIMENTAL
Intervention: Comprehensive medical intervention including medical management and caregiver education
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Comprehensive medical intervention
Number of subjects: 111
Study: 8436638

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg bid) under supervision
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-compliant patients (8 out of 18)
Number of subjects: 18

Group type: COMPARATOR
Intervention: BANA test
Number of subjects: 18
Study: 2878174

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 31767144

Group type: EXPERIMENTAL
Intervention: High FIO2 (0.80)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Low FIO2 (0.3)
Number of subjects: 740
Study: 31647821

Group type: EXPERIMENTAL
Intervention: ImTeCHO mobile‐phone‐and web‐based application
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study: 27550537

Group type: EXPERIMENTAL
Intervention: Lycopene-enriched virgin olive oil spray (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo spray (n = 30)
Number of subjects: 60
Study: 26022639

Group type: COMPARATOR
Intervention: Binary logistic regression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proportional odds regression
Number of subjects: 0
Study: 23789370

Group type: EXPERIMENTAL
Intervention: Rectal suppositories vitaprost plus once a day for 10 days before and after surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pefloxacin 400 mg 2 times a day for 10 days before and after surgery (Control group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rectal suppositories vitaprost plus
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pefloxacin 400 mg 2 times a day (Control group)
Number of subjects: 73
Study: 21972621

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 68

Group type: COMPARATOR
Intervention: Medication (Enteric-coated aspirin)
Number of subjects: 68
Study: 19621668

Group type: EXPERIMENTAL
Intervention: Nizatidine (group N) for 16 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sofalcone (group S) for 16 weeks
Number of subjects: 39
Study: 16706858

Group type: EXPERIMENTAL
Intervention: Endogenous-sustained attention (same-point stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exogenous-transient attention (randomised stimuli)
Number of subjects: 0
Study: 15533466

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection (100 to 200 U of Dysport or Botox)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection
Number of subjects: 13
Study: 11816866

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 9143025

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hematoxylin‐eosin (HE) stain
Number of subjects: 0
Study: 8116561

Group type: EXPERIMENTAL
Intervention: Fructose as a sweetener
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High doses of fructose
Number of subjects: 0
Study: 3426488

Group type: EXPERIMENTAL
Intervention: 600 mg caffeine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31714457

Group type: EXPERIMENTAL
Intervention: Combined training (G1) for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonexercise control (G2)
Number of subjects: 12
Study: 29905759

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (GP)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (GT)
Number of subjects: 236
Study: 27221328

Group type: EXPERIMENTAL
Intervention: Submandibular gland resection
Number of subjects: 5
Study: 25518015

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 64
Study: 22448451

Group type: EXPERIMENTAL
Intervention: Web-based asthma self-management
Number of subjects: 21

Group type: COMPARATOR
Intervention: Paper-based asthma self-management
Number of subjects: 21
Study: 20399993

Group type: EXPERIMENTAL
Intervention: Test formulation of Mycophenolate mofetil (MMF) 500 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Reference formulation of Mycophenolate mofetil (MMF) 500 mg
Number of subjects: 103
Study: 18397979

Group type: EXPERIMENTAL
Intervention: Outpatient 1-year intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: No intervention (control group of children without substantial weight loss)
Number of subjects: 43
Study: 16463851

Group type: EXPERIMENTAL
Intervention: Non-shunted patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Shunted patients
Number of subjects: 68
Study: 12465731

Group type: EXPERIMENTAL
Intervention: Echo-enhanced power Doppler sonography
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional ultrasound or unenhanced power Doppler sonography
Number of subjects: 137
Study: 11272352

Group type: EXPERIMENTAL
Intervention: Iridium-192
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8600885

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2009843

Group type: EXPERIMENTAL
Intervention: Triazolam, 0.125 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 6128230

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin and motilin together infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 0
Study: 31348263

Group type: EXPERIMENTAL
Intervention: Real laser acupuncture (LA), 3 sessions a week for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham laser acupuncture (LA), 3 sessions a week for 2 weeks
Number of subjects: 40
Study: 27641444

Group type: EXPERIMENTAL
Intervention: Electrically induced muscle cramps (EIMCs) in the gastrocnemius medialis of one leg (intervention leg, IL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 10
Study: 27363928

Group type: EXPERIMENTAL
Intervention: Hysteroscopic site-specific local endometrial injury (LEI), n = 60
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (control group), n = 60
Number of subjects: 120
Study: 25279781

Group type: EXPERIMENTAL
Intervention: Onefit P&A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mini Scleral Design (msd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jupiter
Number of subjects: 0
Study: 22326775

Group type: EXPERIMENTAL
Intervention: One dose of PCV7
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Two doses of PCV7
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: One or two doses of PCV7
Number of subjects: 118
Study: 20557905

Group type: EXPERIMENTAL
Intervention: Predictive model including Charlson index and PCT
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Derivation set
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Risk groups based on score
Number of subjects: 412
Study: 17601990

Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamp (1.2 mU x kg(‐1) x min(‐1) insulin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study: 16518992

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels of 93-99 mg/dl
Number of subjects: 6924

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels of 100-125 mg/dl
Number of subjects: 6924

Group type: EXPERIMENTAL
Intervention: BMI of 23-27.5 kg/m2
Number of subjects: 6924

Group type: EXPERIMENTAL
Intervention: BMI > 27.5 kg/m2
Number of subjects: 6924

Group type: EXPERIMENTAL
Intervention: Overall incidence of type 2 diabetes
Number of subjects: 6924

Group type: EXPERIMENTAL
Intervention: Incidence rates by gender
Number of subjects: 6924
Study: 12457019

Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) assessment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neuropsychological measures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ToM-2 (capacity to comprehend other people's mental states)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recent onset of illness, good verbal fluency, low levels of negative and positive symptoms
Number of subjects: 44
Study: 10529122

Group type: EXPERIMENTAL
Intervention: 5 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10